Joaquín Sáez‐Peñataro
A5046363959- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Biosimilars and Bioanalytical Methods
- Research on Leishmaniasis Studies
- SARS-CoV-2 and COVID-19 Research
- Statistical Methods in Clinical Trials
- Immunotherapy and Immune Responses
- Cardiac Arrhythmias and Treatments
- Drug-Induced Adverse Reactions
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Vaccine Coverage and Hesitancy
- Drug-Induced Hepatotoxicity and Protection
- Biomedical Ethics and Regulation
- Cardiovascular Syncope and Autonomic Disorders
- Liver Diseases and Immunity
- Antiplatelet Therapy and Cardiovascular Diseases
- Prenatal Substance Exposure Effects
- Integrated Circuits and Semiconductor Failure Analysis
- Contact Dermatitis and Allergies
- Pericarditis and Cardiac Tamponade
- Radiopharmaceutical Chemistry and Applications
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2022-2024
Hospital Clínic de Barcelona
2015-2024
Universitat de Barcelona
2012-2024
Hospital Universitari de Vic
2013
Universitat de Miguel Hernández d'Elx
2011
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ malignancies. Patients received cyclophosphamide fludarabine followed by at a dose 0.4-5 × 106 cells/kg, initially as single later split into 3 fractions (10%, 30%, 60%) full depending on absence cytokine release syndrome (CRS). 58 were included, which 47 therapy: 38 acute lymphoblastic leukemia (ALL), 8 non-Hodgkin's lymphoma, 1...
Abstract Purpose: B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we present clinical...
Recent Cryptococcus gattii infections in humans and animals, including several outbreaks goats, were the basis of this environmental survey six provinces Spain. A total 479 samples from 20 tree species studied. was found for first time autochthonous Mediterranean trees Fourteen isolates pathogen obtained seven three different species: 12 carob (Ceratonia siliqua), one stone pine (Pinus halepensis) another eucalyptus (Eucalyptus camaldulensis). All C. genotype AFLP4/VGI mating type alpha, to...
Abstract Drug‐induced liver injury (DILI) is a challenging disorder for hepatologists. We aimed to assess the pattern and causes of DILI in tertiary hospital. registered prospectively all patients referred with suspicion from 2018 2023. A total 106 fulfilled diagnostic criteria (30 caused by paracetamol were excluded; number 76). The was hepatocellular 55 (72%). Drugs causing antineoplastic (26%), antibiotics (24%), analgesics (12%), recreational drugs (9%). Regarding clinical outcomes, 39...
Summary Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor (CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in CART19‐BE‐01 trial. Here we report updated outcomes patients with NHL treated var‐cel. B‐cell recovery was compared acute lymphoblastic leukaemia (ALL). Forty‐five were treated. Cytokine release syndrome (any grade) occurred 84% (4% grade ≥3) and neurotoxicity 7% (2% ≥3). The objective response rate 73% at Day +100, 3‐year...
Pericarditis is the most frequent cardiac manifestation of systemic lupus erythematosus (SLE). However, a large pericardial effusion as initial disease infrequent, especially when it associated with myocardial damage. We describe an unusual case young female pleuropericarditis and severe dysfunction SLE.
The comparative safety profile of SARS-Cov2 vaccines requires further characterization in real-world settings. aim the VigilVacCOVID study was to assess short-term BNT162b2 and mRNA-1273 during vaccination campaign healthcare professionals (HCPs) solid-organ transplant recipients (SOTRs) at a hospital clinic. We conducted an observational, prospective, single-center, post-authorization characterize adverse reactions (ARs) after vaccination. primary endpoint between-vaccine differences (HCPs...
<div>AbstractPurpose:<p>B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we...
<div>AbstractPurpose:<p>B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we...
<p>Figure 13. Progression-free survival according to triple-refractoriness, high-risk cytogenetics, extramedullary involvement and ISS.</p>
<p>Figure 12. Time from measurable residual disease positivity to overt relapse</p>
<p>Figure 13. Progression-free survival according to triple-refractoriness, high-risk cytogenetics, extramedullary involvement and ISS.</p>
<p>Figure 10. Progression-free and overall survival according to cytokine values</p>
<p>Figure 11. Progression-free survival according to MRD-negative sensitivity on day 28.</p>
<p>Figure 10. Progression-free and overall survival according to cytokine values</p>
<p>Figure 11. Progression-free survival according to MRD-negative sensitivity on day 28.</p>
<p>Figure 14. Progression-free survival according to involved serum free-light chain levels below the lower limit of normality (green) on (A) days 28 and (B) 100.</p>